Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Wellcome Centre for Molecular Parasitology · University of Glasgow · +14 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
844
total citations
- FWCI
- 81.31
- Percentile
- 100%
- References
- 27
Citations per year
Authors
15Topics & keywords
Topics
Keywords
- Secukinumab
- Medicine
- Psoriatic arthritis
- Placebo
- Internal medicine
- Clinical endpoint
- Rheumatology
- Arthritis
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.